<DOC>
	<DOCNO>NCT01342692</DOCNO>
	<brief_summary>In order improve overall survival benefit observe AZA high risk MDS , combination active drug MDS must test . Among drug demonstrate active single agent MDS preclinical potential additive synergistic activity AZA Histone deacetylase ( HDAC ) inhibitor include Valproic acid , Lenalidomide idarubicin . Phase I study already conduct conduct combine agent demethylating agent , show low toxicity profile significant response high risk MDS . In phase II randomize trial , want identify promising combination Azacitidine another drug ( among 3 drug : Valproic acid , Lenalidomide Idarubicin ) high risk MDS , comparison Azacitidine alone . Of note , base efficacy toxicity , one several combination may stop , others , previously test phase I trial , include protocol amendment .</brief_summary>
	<brief_title>Best Promising Drug Association With Azacitidine Higher Risk Myelodysplastic Syndromes</brief_title>
	<detailed_description>The main objective phase II randomize trial identify , among 3 combination Azacitidine another drug evaluate simultaneously , promise combination ( ) treatment high risk MDS ( IPSS Int-2 High ) compare Azacitidine alone . The 3 test drug combination Azacitidine : Valproic Acid , Lenalidomide Idarubicin . The aim trial identify , situation several potentially interesting drug test combination AZA exist , promise combination ( ) base efficacy compare azacitidine alone , base two-stage design allow formal efficacy comparison K=3 investigational treatment group control group .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>age &gt; =18 year Must able adhere study visit schedule protocol requirement Documented diagnosis MDS , include AREBt accord FAB classification CMML ( WBC &lt; 13,000/mm3 ) meet IPSS criterion intermediate2 highrisk . Patients willing use adequate contraceptive method duration study 1 . Treatment AZA Decitabine previous 6 month 2 . Previous treatment HDAC inhibitor ( Sodium valproate , Vorinostat , depsipeptide ou NSC630176 , MS 275 , LAQ824 , PXD101 , LBH589 , MGCD0103 , CRA024781 , etc ) . If Sodium Valproate ( Depakine® ) use seizure , washout period least 30 day require appropriate treatment replacement perform . 3 . Ongoing treatment corticosteroid exceed 30mg prednisone per day . A wash period least 7 day require . 4 . HIV infection 5 . Creatinine &gt; 1.5 ULN 6 . Serum AST ALT &gt; 3.0 x upper limit normal ( ULN ) 7 . Serum total bilirubin &gt; 1.5 mg/dl ( except unconjugated hyperbilirubinemia due Gilbert 's disease secondary MDS ) . 8 . ≥ grade2 neuropathy 9 . Previous history Acute myeloblastic leukemia ( marrow blast &gt; 30 % ) 10 . Previous history allogeneic stem cell transplantation 11 . Contraindication Anthracyclines : Myocardiopathy , uncontrolled infection , serious renal hepatic impairment ; associate yellow fever vaccine 12 . Known hypersensitivity active substance excipients Vidaza® , valproate , divalproate , valpromide , Lenalidomide , thalidomide , idarubicin and/or anthracyclines 13 . Patients history severe congestive heart failure , clinically unstable cardiac pulmonary disease 14 . All hepatitis know personal familial severe hepatitis , particularly due drug 15 . Depression suicidal tendency 16 . Use MILLEPERTUIS , mefloquine 17 . No medical insurance French Health system 18 . Prior history malignancy MDS ( except basal cell squamous cell carcinoma carcinoma situ cervix breast ) unless subject free disease ≥ 3 year . 19 . Pregnant lactating female 20 . Eligibility allogeneic stem cell transplantation 21. alter general condition , WHO performance status 4 , life expectancy le 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>